Stock Traders Purchase High Volume of Put Options on Questcor Pharmaceuticals (QCOR)
Questcor Pharmaceuticals (NASDAQ:QCOR) saw unusually large options trading on Friday. Stock traders bought 18,979 put options on the company, American Banking & Market News reports. This is an increase of approximately 657% compared to the typical daily volume of 2,506 put options.
In other Questcor Pharmaceuticals news, Director Virgil Thompson sold 5,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $63.75, for a total transaction of $318,750.00. Following the completion of the transaction, the director now directly owns 29,867 shares in the company, valued at approximately $1,904,021. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of research firms have recently commented on QCOR. Analysts at Goldman Sachs Group Inc. initiated coverage on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) in a research note to investors on Tuesday, September 17th. They set a “neutral” rating and a $65.27 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Janney Montgomery Scott raised their price target on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) to $90.00 in a research note to investors on Tuesday, August 27th. Finally, analysts at Janney Montgomery Scott raised their price target on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) from $65.00 to $90.00 in a research note to investors on Tuesday, August 27th.
Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $69.72.
Questcor Pharmaceuticals (NASDAQ:QCOR) opened at 55.33 on Monday. Questcor Pharmaceuticals has a one year low of $17.25 and a one year high of $74.76. The stock has a 50-day moving average of $66.31 and a 200-day moving average of $45.09. The company has a market cap of $3.261 billion and a price-to-earnings ratio of 14.85.
Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Tuesday, July 30th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.96 by $0.16. The company had revenue of $184.60 million for the quarter, compared to the consensus estimate of $168.96 million. During the same quarter last year, the company posted $0.65 earnings per share. Questcor Pharmaceuticals’s revenue was up 64.1% compared to the same quarter last year. On average, analysts predict that Questcor Pharmaceuticals will post $4.83 earnings per share for the current fiscal year.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.